Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RSV-F Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

NCT06890416
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

NCT02624947
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV F vaccine with adjuvant, Formulation buffer
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
4,636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
49
States / cities
Birmingham, Alabama • Cullman, Alabama • Fort Defiance, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

NCT04908683
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Interventions
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
25,236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
156
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 15, 2026, 11:08 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212
View directory record Official record
Conditions
Lower Respiratory Tract Illness
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
38,861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

NCT04424316
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 49 Years · Female only
Enrollment
14,727 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
363
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

NCT02266628
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
1,599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Dose-Ranging Study in Women

NCT01960686
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

NCT05281263
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CPI-RSV-F Vaccine (BLB-201)
Biological
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 15, 2026, 11:08 AM EDT
Not yet recruiting Phase 4 Interventional

RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

NCT07296120
View directory record Official record
Conditions
CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
Interventions
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Biological
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
View directory record Official record
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967
View directory record Official record
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV-F Particle Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

NCT01709019
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

NCT06473519
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF MDV, RSVpreF SDV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
6
States / cities
South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154
View directory record Official record
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF 120 µg, RSVpreF 60 µg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

NCT02593071
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 15, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

NCT07768345
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Decatur, Georgia • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

NCT02830932
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 15, 2026, 11:08 AM EDT